Leading Biotech Giants Set Up Shop In China
This article was originally published in PharmAsia News
Two of the world's leading biotech companies, Biogen Idec and Genzyme, set up branch offices in Shanghai last year. Even as their licensing revenue from multinational pharmaceutical corporations increases, these biotech firms have decided to enter the Chinese market to build up their own sales and distribution networks. Biogen Idec will be investing heavily in China over the next five years while Genzyme plans to set up a plant in Beijing. (Click here for more)
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.